EDX Medical Group and Caris Life Sciences Collaborate to Distribute Molecular Profiling Across the UK & Nordic Countries
Shots:
- EDX Medical Group & Caris have entered into 3yrs. mutually exclusive distribution agreement, as per which Caris' advanced molecular profiling services will be offered across the UK and Nordic countries for clinical & research use
- Caris' tumor & liquid biopsy molecular profiling solutions and AI-based services will be provided via EDX Medical in the UK, Sweden, Denmark, Norway & Finland, with more regions & products to be added later
- Caris’ molecular profiling solution analyzes DNA, RNA & proteins to create a molecular blueprint, making precise cancer treatment decisions. Tumor biomarker analysis also help HCPs make personalized treatment decisions
Ref: EDX Medical Group | Image: EDX Medical Group & Caris Life Sciences
Related News:- Caris Life Sciences Collaborates with Merck KGaA to Discover and Develop Antibody Drug Conjugate for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
